Profound Medical (PROF) Competitors

$6.73 -0.16 (-2.32%)

Closing price 04:00 PM Eastern

Extended Trading

$6.74 +0.01 (+0.22%)

As of 04:04 PM Eastern

PROF vs. BLFS, TNDM, INMD, DRTS, and BVS

Should you buy Profound Medical stock or one of its competitors? MarketBeat compares Profound Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profound Medical include BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), InMode (INMD), Alpha Tau Medical (DRTS), and Bioventus (BVS). These companies are all part of the "medical equipment" industry.

How does Profound Medical compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioLife Solutions has higher revenue and earnings than Profound Medical. BioLife Solutions is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$96.21M	11.71	-$4.59M	-$0.08	N/A
Profound Medical	$16.10M	15.19	-$42.57M	-$1.24	N/A

BioLife Solutions presently has a consensus target price of $32.00, indicating a potential upside of 38.83%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 78.31%. Given Profound Medical's higher probable upside, analysts clearly believe Profound Medical is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, BioLife Solutions and BioLife Solutions both had 2 articles in the media. Profound Medical's average media sentiment score of 0.60 beat BioLife Solutions' score of -0.18 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market.

BioLife Solutions has a net margin of -2.80% compared to Profound Medical's net margin of -206.76%. BioLife Solutions' return on equity of 1.81% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	-2.80%	1.81%	1.65%
Profound Medical	-206.76%	-78.88%	-64.06%

Summary

BioLife Solutions beats Profound Medical on 11 of the 15 factors compared between the two stocks.

How does Profound Medical compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Tandem Diabetes Care has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

In the previous week, Tandem Diabetes Care had 5 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for Tandem Diabetes Care and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.60 beat Tandem Diabetes Care's score of 0.31 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.9% of Profound Medical shares are held by institutional investors. 2.1% of Tandem Diabetes Care shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profound Medical has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01B	0.94	-$204.71M	-$1.40	N/A
Profound Medical	$16.10M	15.19	-$42.57M	-$1.24	N/A

Tandem Diabetes Care has a net margin of -9.20% compared to Profound Medical's net margin of -206.76%. Tandem Diabetes Care's return on equity of -53.88% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Profound Medical	-206.76%	-78.88%	-64.06%

Tandem Diabetes Care currently has a consensus target price of $29.63, suggesting a potential upside of 113.79%. Profound Medical has a consensus target price of $12.00, suggesting a potential upside of 78.31%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Tandem Diabetes Care beats Profound Medical on 11 of the 17 factors compared between the two stocks.

How does Profound Medical compare to InMode?

InMode (NASDAQ:INMD) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

InMode has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

InMode has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$370.49M	2.39	$93.83M	$1.36	10.28
Profound Medical	$16.10M	15.19	-$42.57M	-$1.24	N/A

68.0% of InMode shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

InMode has a net margin of 23.27% compared to Profound Medical's net margin of -206.76%. InMode's return on equity of 13.47% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Profound Medical	-206.76%	-78.88%	-64.06%

InMode presently has a consensus target price of $16.00, indicating a potential upside of 14.41%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 78.31%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Profound Medical had 1 more articles in the media than InMode. MarketBeat recorded 2 mentions for Profound Medical and 1 mentions for InMode. Profound Medical's average media sentiment score of 0.60 beat InMode's score of 0.00 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

InMode beats Profound Medical on 10 of the 14 factors compared between the two stocks.

How does Profound Medical compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.

Profound Medical has higher revenue and earnings than Alpha Tau Medical. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A
Profound Medical	$16.10M	15.19	-$42.57M	-$1.24	N/A

Alpha Tau Medical currently has a consensus target price of $11.50, indicating a potential upside of 7.68%. Profound Medical has a consensus target price of $12.00, indicating a potential upside of 78.31%. Given Profound Medical's higher probable upside, analysts clearly believe Profound Medical is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Alpha Tau Medical had 8 more articles in the media than Profound Medical. MarketBeat recorded 10 mentions for Alpha Tau Medical and 2 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.60 beat Alpha Tau Medical's score of -0.06 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Tau Medical has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

Alpha Tau Medical has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Alpha Tau Medical's return on equity of -70.71% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-70.71%	-53.10%
Profound Medical	-206.76%	-78.88%	-64.06%

Summary

Alpha Tau Medical beats Profound Medical on 9 of the 15 factors compared between the two stocks.

How does Profound Medical compare to Bioventus?

Profound Medical (NASDAQ:PROF) and Bioventus (NASDAQ:BVS) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Bioventus has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profound Medical	$16.10M	15.19	-$42.57M	-$1.24	N/A
Bioventus	$568.09M	1.57	$22.73M	$0.41	26.00

Profound Medical currently has a consensus price target of $12.00, suggesting a potential upside of 78.31%. Bioventus has a consensus price target of $14.00, suggesting a potential upside of 31.33%. Given Profound Medical's higher probable upside, analysts plainly believe Profound Medical is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Bioventus has a net margin of 4.94% compared to Profound Medical's net margin of -206.76%. Bioventus' return on equity of 29.97% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profound Medical	-206.76%	-78.88%	-64.06%
Bioventus	4.94%	29.97%	9.52%

47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 62.9% of Bioventus shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profound Medical has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Bioventus has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

In the previous week, Profound Medical had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for Profound Medical and 1 mentions for Bioventus. Profound Medical's average media sentiment score of 0.60 beat Bioventus' score of -1.00 indicating that Profound Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Bioventus beats Profound Medical on 12 of the 17 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PROF vs. The Competition

Export

Metric	Profound Medical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$250.37M	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.27%
P/E Ratio	-5.43	17.04	20.79	25.04
Price / Sales	15.19	251.21	531.21	72.17
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	4.10	4.39	9.81	6.83
Net Income	-$42.57M	$74.99M	$3.55B	$335.69M
7 Day Performance	-5.74%	-4.89%	-2.07%	-2.03%
1 Month Performance	1.20%	-8.30%	-3.90%	-1.90%
1 Year Performance	34.87%	28.66%	29.39%	27.36%

Profound Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PROF Profound Medical	1.5504 of 5 stars	$6.73 -2.3%	$12.00 +78.3%	+46.3%	$250.37M	$16.10M	N/A	150
BLFS BioLife Solutions	2.6168 of 5 stars	$21.23 -2.3%	$32.00 +50.7%	-5.5%	$1.04B	$96.21M	N/A	440
TNDM Tandem Diabetes Care	2.5303 of 5 stars	$14.69 -0.5%	$29.89 +103.5%	-41.4%	$1.01B	$1.01B	N/A	2,500	Positive News Analyst Forecast
INMD InMode	1.3919 of 5 stars	$13.83 +0.4%	$16.00 +15.7%	-3.9%	$876.27M	$370.49M	10.17	480
DRTS Alpha Tau Medical	1.8207 of 5 stars	$9.88 -4.4%	$9.67 -2.2%	+259.5%	$869.54M	N/A	N/A	80	News Coverage Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PROF) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profound Medical (PROF) Competitors

PROF vs. BLFS, TNDM, INMD, DRTS, and BVS

How does Profound Medical compare to BioLife Solutions?

Summary

How does Profound Medical compare to Tandem Diabetes Care?

Summary

How does Profound Medical compare to InMode?

Summary

How does Profound Medical compare to Alpha Tau Medical?

Summary

How does Profound Medical compare to Bioventus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profound Medical (PROF) Competitors

PROF vs. BLFS, TNDM, INMD, DRTS, and BVS

How does Profound Medical compare to BioLife Solutions?

Do insiders and institutionals believe in BLFS or PROF?

Which has better valuation & earnings, BLFS or PROF?

Do analysts recommend BLFS or PROF?

Does the media favor BLFS or PROF?

Which has more risk & volatility, BLFS or PROF?

Is BLFS or PROF more profitable?

Summary

How does Profound Medical compare to Tandem Diabetes Care?

Which has more risk & volatility, TNDM or PROF?

Does the media favor TNDM or PROF?

Do institutionals & insiders hold more shares of TNDM or PROF?

Which has better valuation and earnings, TNDM or PROF?

Is TNDM or PROF more profitable?

Do analysts rate TNDM or PROF?

Summary

How does Profound Medical compare to InMode?

Which has more volatility and risk, INMD or PROF?

Which has preferable valuation and earnings, INMD or PROF?

Do institutionals and insiders believe in INMD or PROF?

Is INMD or PROF more profitable?

Do analysts prefer INMD or PROF?

Does the media refer more to INMD or PROF?

Summary

How does Profound Medical compare to Alpha Tau Medical?

Which has stronger earnings & valuation, DRTS or PROF?

Do analysts prefer DRTS or PROF?

Do insiders and institutionals believe in DRTS or PROF?

Does the media refer more to DRTS or PROF?

Which has more risk & volatility, DRTS or PROF?

Is DRTS or PROF more profitable?

Summary

How does Profound Medical compare to Bioventus?

Which has preferable earnings and valuation, PROF or BVS?

Do analysts recommend PROF or BVS?

Is PROF or BVS more profitable?

Do insiders & institutionals hold more shares of PROF or BVS?

Which has more risk & volatility, PROF or BVS?

Does the media prefer PROF or BVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PROF vs. The Competition

Profound Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools